logo-loader
viewSkinBioTherapeutics PLC

Successor sought to build £500mln company at SkinBioTherapeutics

Dr Cath O'Neill, CEO of  SkinBioTherapeutics PLC (LON:SBTX), says her successor will have the skills to take the company to commercialisation.
The boss, who invented the skin care technology and the SkinBiotix repair and protect cream, tells Proactive London "it's now the job of someone else with a different skillset to build the business into a £500mln company."
O'Neill has been with life sciences company since the beginning and is looking to return to her scientific roots.

Quick facts: SkinBioTherapeutics PLC

Price: - -

AIM:SBTX
Market: AIM
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of SkinBioTherapeutics PLC named herein, including the promotion by the Company of SkinBioTherapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

SkinBioTherapeutics inks commercial deal with FTSE 100 chemical firm Croda

SkinBioTherapeutics PLC's (LON:SBTX) CEO Stuart Ashman speaks to Proactive London's Andrew Scott after announcing they've inked a commercial agreement for its skincare product with FTSE 100 speciality chemical company Croda International Plc (LON:CRDA). Ashman says it's a significant first...

on 20/11/19

2 min read